期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 17, 期 8, 页码 1025-1033出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2010.04.020
关键词
Alzheimer's disease; Dementia; PP2A; Sodium selenate; Tau
资金
- Melbourne Urology Trust
- Cybec Trust
- Royal Melbourne Hospital Neuroscience Foundation
- NHMRC Medical Postgraduate Scholarship
Neurofibrillary tangles composed of abnormally hyperphosphorylated tau protein are a hallmark of Alzheimer's disease (AD) and related tauopathies. Tau hyperphosphorylation is thought to promote aggregation with subsequent tangle formation. Reducing tau phosphorylation by boosting the activity of the key phosphatase/s that mediate dephosphorylation of tau could be a viable clinical strategy in AD. One of the key phosphatases implicated in regulating tau protein phosphorylation is the serine-threonine phosphatase PP2A. We have determined that sodium selenate can act as a specific agonist for PP2A, significantly boosting phosphatase activity. Acute treatment of either neuroblastoma cells or normal aged mice with sodium selenate rapidly reduced tau protein phosphorylation. Sodium selenate-treated transgenic TAU441 mice had significantly lower levels of phospho- and total tau levels in the hippocampus and amygdala compared with controls and exhibited significantly improved spatial learning and memory on the Morris Water Maze task. Sodium selenate is a specific activator of PP2A with excellent oral bio-availability, and favourable central nervous system penetrating properties. Clinical studies in patients with AD are envisaged in the near future. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据